| Literature DB >> 23642919 |
Shannon D Thomas1, Robert R A McDonald2, Ramon L Varcoe3.
Abstract
Drug-eluting balloons (DEBs) coated with the antiproliferative agent paclitaxel may improve primary patency by reducing recurrent luminal stenosis. A proportion of the active drug and excipient coating are known to embolize distally, but until now, there have been no reports of adverse events resulting from their use. We report an unusual case of a painful nodular, biopsy specimen-proven vasculitic rash that afflicted the ipsilateral lower limb of a patient after superficial femoral artery treatment with a DEB. This adverse event may have implications for the use of DEB in this and other vascular territories.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23642919 DOI: 10.1016/j.jvs.2013.03.013
Source DB: PubMed Journal: J Vasc Surg ISSN: 0741-5214 Impact factor: 4.268